115 related articles for article (PubMed ID: 38103365)
1. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract][Full Text] [Related]
2. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Köbel M; Kang EY; Weir A; Rambau PF; Lee CH; Nelson GS; Ghatage P; Meagher NS; Riggan MJ; Alsop J; Anglesio MS; Beckmann MW; Bisinotto C; Boisen M; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; Deen S; El-Bahrawy MA; Elishaev E; Erber R; Fereday S; ; Fischer A; Gayther SA; Barquin-Garcia A; Gentry-Maharaj A; Gilks CB; Gronwald H; Grube M; Harnett PR; Harris HR; Hartkopf AD; Hartmann A; Hein A; Hendley J; Hernandez BY; Huang Y; Jakubowska A; Jimenez-Linan M; Jones ME; Kennedy CJ; Kluz T; Koziak JM; Lesnock J; Lester J; Lubiński J; Longacre TA; Lycke M; Mateoiu C; McCauley BM; McGuire V; Ney B; Olawaiye A; Orsulic S; Osorio A; Paz-Ares L; Ramón Y Cajal T; Rothstein JH; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Steed H; Storr SJ; Talhouk A; Traficante N; Wang C; Whittemore AS; Widschwendter M; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Campbell I; Cook LS; DeFazio A; Doherty JA; Fasching PA; Fortner RT; García MJ; Goodman MT; Goode EL; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Kommoss S; Le ND; Martin SG; Menon U; Modugno F; Pharoah PD; Schildkraut JM; Sieh W; Staebler A; Sundfeldt K; Swerdlow AJ; Ramus SJ; Brenton JD
J Pathol Clin Res; 2023 May; 9(3):208-222. PubMed ID: 36948887
[TBL] [Abstract][Full Text] [Related]
3. WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis.
Sallum LF; Andrade L; Ramalho S; Ferracini AC; de Andrade Natal R; Brito ABC; Sarian LO; Derchain S
Oncotarget; 2018 Mar; 9(22):15818-15827. PubMed ID: 29662608
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract][Full Text] [Related]
5. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
[TBL] [Abstract][Full Text] [Related]
6. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
7. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients.
Chen M; Yao S; Cao Q; Xia M; Liu J; He M
Oncotarget; 2017 Dec; 8(64):107877-107885. PubMed ID: 29296209
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
9. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
10. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
[TBL] [Abstract][Full Text] [Related]
11. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Tołoczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón Y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubiński J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Głaz A; Chenevix-Trench G; Cazorla A; Brucker SY; ; Alsop J; Whittemore AS; Steed H; Staebler A; Moysich KB; Menon U; Koziak JM; Kommoss S; Kjaer SK; Kelemen LE; Karlan BY; Huntsman DG; Høgdall E; Gronwald J; Goodman MT; Gilks B; García MJ; Fasching PA; de Fazio A; Deen S; Chang-Claude J; Candido Dos Reis FJ; Campbell IG; Brenton JD; Bowtell DD; Benítez J; Pharoah PDP; Köbel M; Ramus SJ; Goode EL
Mayo Clin Proc; 2018 Mar; 93(3):307-320. PubMed ID: 29502561
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
13. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
[TBL] [Abstract][Full Text] [Related]
14. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
[TBL] [Abstract][Full Text] [Related]
15. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.
Wohlmuth C; Djedovic V; Kjaer SK; Jensen A; Glasspool R; Roxburgh P; DeFazio A; Johnatty SE; Webb PM; Modugno F; Lambrechts D; Schildkraut JM; Berchuck A; Thomsen LCV; Bjorge L; Høgdall E; Høgdall CK; Goode EL; Winham SJ; Matsuo K; Karlan BY; Lester J; Goodman MT; Thompson PJ; Pejovic T; Riggan MJ; Lajkosz K; Tone A; May T
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454861
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
[TBL] [Abstract][Full Text] [Related]
17. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
18. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
